https://pittplusme.org/study/1246
UPCI 15-101 - AML
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Are you age 60 or up, are in complete remission after receiving treatment for acute myeloid leukemia (AML), but are not a candidate for stem cell transplant? If so, you may be eligible to participate in a study that is testing an investigational drug to see if can extend your remission period. Study participation involves a 30-minute intravenous infusion once every 3 weeks for up to 2 years.
IRB: STUDY19040090
- HCC 15-101: A Phase II study of Pembrolizumab as Post-Remission Treatment of Patients Age 60 or Older with AML Who Are Not Transplantation Candidates
AGE:
18 and up
DURATION:
up to 2 years
LOCATION:
UPMC Cancer Center
COMPENSATION:
NONE
SHARE STUDY
